Characterization of mouse melanoma cell lines by their mortal malignancy using an experimental metastatic model
- PMID: 11833741
- DOI: 10.1016/s0024-3205(01)01454-0
Characterization of mouse melanoma cell lines by their mortal malignancy using an experimental metastatic model
Abstract
We characterized the metastatic ability and mortality of four different mouse melanoma cell lines, B16-F0, -F1, -F10 and -BL6. B16-F0 is the parent cell line. B16-F1 was obtained by a one-time selective procedure and B16-F10 by a ten-time selective procedure using Fidler's method. B16-BL6 derived from B16-F10 has much more invasive activity than B16-F10. To investigate the difference in mortal malignancy among B16-F0, -F1, -F10 and -BL6, we examined the survival time of syngeneic C57BL/6Cr mice intravenously inoculated with these cells. As a control, we used the C57BL/6J-embryo mouse fibroblast-like semi-normal cell line. The ability to form lung metastatic nodules in mice gradually increased in the order: B16-F0, -F1, and -F10 (=-BL6). C57BL/6J-embryo cell (1 x 10(5)/mouse)-inoculated mice survived for over 46 days. B16-F0, -F1, -F10 and -BL6 (1 x 10(5)/mouse)-inoculated mice survived 31.4+/-4.4 (7), 25.7+/-2.8 (7), 23.6+/-1.5 (7) and 25.3+/-2.3 (7) days [mean+/-S.D. (number of mice)], respectively. According to the Mann-Whitney test, the B16-F0 inoculated group versus -F1 inoculated group (P<0.05), -F0 inoculated group versus -BL6 inoculated group (P<0.05), and -F0 inoculated group versus -F10 inoculated group (P<0.01) were significantly different, but the B16-F1 group versus -F10 group, -F1 group versus -BL6 group, and -F10 group versus -BL6 group were not. These results suggest that mortal malignancy is not necessarily correlated with lung-colonizing potential and even only one-time selected B16-F0 mouse melanoma cells are useful as an experimental metastatic model in vivo.
Similar articles
-
Suppression of B16 melanoma lung colonization by syngeneic monoclonal antibodies.Cancer Res. 1987 May 15;47(10):2696-703. Cancer Res. 1987. PMID: 3552203
-
Epigenetic transfer of metastatic activity by uptake of highly metastatic B16 melanoma cell-released exosomes.Exp Oncol. 2006 Jun;28(2):126-31. Exp Oncol. 2006. PMID: 16837903
-
Role of thymosin beta4 in tumor metastasis and angiogenesis.J Natl Cancer Inst. 2003 Nov 19;95(22):1674-80. doi: 10.1093/jnci/djg100. J Natl Cancer Inst. 2003. PMID: 14625258
-
Specificity of the suppression of metastatic phenotype by tyrosine and phenylalanine restriction.Clin Exp Metastasis. 1990 Sep-Oct;8(5):393-416. doi: 10.1007/BF00058152. Clin Exp Metastasis. 1990. PMID: 2202533 Review.
-
Nitrile-Containing Terpyridyl Zn(II)-Coordination Polymer-Based Metallogelators Displaying Helical Structures: Synthesis, Structures, and "Druglike" Action against B16-F10 Melanoma Cells.ACS Appl Mater Interfaces. 2023 May 31;15(21):25098-25109. doi: 10.1021/acsami.2c05338. Epub 2022 Jun 20. ACS Appl Mater Interfaces. 2023. PMID: 35723469 Review.
Cited by
-
NF-kappaB regulation of endothelial cell function during LPS-induced toxemia and cancer.J Clin Invest. 2006 Nov;116(11):2955-63. doi: 10.1172/JCI27392. Epub 2006 Oct 19. J Clin Invest. 2006. PMID: 17053836 Free PMC article.
-
Morphological features of single cells enable accurate automated classification of cancer from non-cancer cell lines.Sci Rep. 2021 Dec 21;11(1):24375. doi: 10.1038/s41598-021-03813-8. Sci Rep. 2021. PMID: 34934149 Free PMC article.
-
The effects of patchouli alcohol and combination with cisplatin on proliferation, apoptosis and migration in B16F10 melanoma cells.J Cell Mol Med. 2023 May;27(10):1423-1435. doi: 10.1111/jcmm.17745. Epub 2023 Apr 10. J Cell Mol Med. 2023. PMID: 37038620 Free PMC article.
-
Carbohydrate ligand engagement with CD11b enhances differentiation of tumor-associated myeloid cells for immunotherapy of solid cancers.J Immunother Cancer. 2023 Jun;11(6):e006205. doi: 10.1136/jitc-2022-006205. J Immunother Cancer. 2023. PMID: 37399354 Free PMC article.
-
FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma.Cancer Cell. 2025 Mar 10;43(3):428-445.e6. doi: 10.1016/j.ccell.2025.02.001. Epub 2025 Feb 27. Cancer Cell. 2025. PMID: 40020669
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous